Publications


Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future;
Sharma, S, Leung, WK & Heslop, H 2020, Current Stem Cell Reports, vol. 6, no. 2, pp. 17-29. https://doi.org/10.1007/s40778-020-00170-6

Sensitizing Burkitt lymphoma to EBV-CTLs;
Heslop, H 2020, Blood, vol. 135, no. 21, pp. 1822-1823. https://doi.org/10.1182/blood.2020005492

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8);
Goldstein, LJ, Perez, RP, Yardley, D, Han, LK, Reuben, JM, Gao, H, McCanna, S, Butler, B, Ruffini, PA, Liu, Y, Rosato, RR & Chang, JC 2020, Breast Cancer Research, vol. 22, no. 1, 52. https://doi.org/10.1186/s13058-020-01294-7

Spironolactone in pulmonary arterial hypertension: results of a cross-over study;
Safdar, Z, Frost, AE, Basant, A, Deswal, A, O’Brian Smith, E & Entman, M 2020, Pulmonary Circulation, vol. 10, no. 2. https://doi.org/10.1177/2045894019898030

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs;
Reddy, TP, Choi, DS, Anselme, AC, Qian, W, Chen, W, Lantto, J, Horak, ID, Kragh, M, Chang, JC & Rosato, RR 2020, Breast cancer research : BCR, vol. 22, no. 1. https://doi.org/10.1186/s13058-020-01280-z

Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial;
Preston, IR, Burger, CD, Bartolome, S, Safdar, Z, Krowka, M, Sood, N, Ford, HJ, Battarjee, WF, Chakinala, MM, Gomberg-Maitland, M & Hill, NS 2020, Journal of Heart and Lung Transplantation, vol. 39, no. 5, pp. 464-472. https://doi.org/10.1016/j.healun.2019.12.008

Multimedia Technology Used to Supplement Patient Consent for Mohs Micrographic Surgery;
West, L, Srivastava, D, Goldberg, LH & Nijhawan, RI 2020, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], vol. 46, no. 5, pp. 586-590. https://doi.org/10.1097/DSS.0000000000002134

Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network;
Levine, JE, Antin, JH, Allen, CE, Burroughs, LM, Cooke, KR, Devine, S, Heslop, H, Nakamura, R, Talano, JA, Yanik, G & DiFronzo, N 2020, Biology of Blood and Marrow Transplantation, vol. 26, no. 5, pp. e94-e100. https://doi.org/10.1016/j.bbmt.2020.01.024

The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study;
Glassner, K, Oglat, A, Duran, A, Koduru, P, Perry, C, Wilhite, A & Abraham, BP 2020, Journal of Digestive Diseases, vol. 21, no. 5, pp. 264-271. https://doi.org/10.1111/1751-2980.12867

CRISPR-Edited Immune Effectors: The End of the Beginning;
Mo, F, Heslop, H & Mamonkin, M 2020, Molecular Therapy, vol. 28, no. 4, pp. 995-996. https://doi.org/10.1016/j.ymthe.2020.03.009
Live Chat Available